Traders should monitor for any definitive licensing agreement or equity financing announcement, as the company's cash runway extends only into Q4 2026. The advanced term sheet negotiations provide a potential catalyst, but the going concern risk and lack of guaranteed funding make the stock highly speculative and binary.
Price Chart
Executive Summary
Vivoryon Therapeutics reported H1 2026 results with zero revenue, a net loss of EUR 3.4M (improved from EUR 5.5M), and cash of EUR 2.4M sufficient only into Q4 2026. The company highlighted advanced term sheet negotiations for a potential licensing deal for varoglutamstat in diabetic kidney disease, but the going concern risk and lack of funding for the planned Phase 2b study dominate the outlook.
Key Financial Metrics
Key Facts
- Cash and cash equivalents of EUR 2.4M as of June 30, 2026, down from EUR 5.6M at Dec 31, 2025.
- Net loss of EUR 3.4M for H1 2026 vs EUR 5.5M in H1 2025.
- Revenues were zero in both H1 2026 and H1 2025.
- Cash runway guidance: sufficient to fund operations into Q4 2026 only.
- Company concluded it has a going concern risk for FY 2026, dependent on additional funding.
- Advanced term sheet negotiations for a potential licensing agreement for varoglutamstat are ongoing, but no guarantee of any transaction.
- Planned Phase 2b DKD study initiation is subject to securing additional funding/partnership.
- R&D expenses decreased to EUR 1.7M from EUR 2.8M, driven by lower clinical development costs.
- Loss per share improved to EUR (0.11) from EUR (0.21).
Financial Impact
Cash burn of EUR 3.2M in H1 2026; cash runway only into Q4 2026; going concern risk without new funding.
Risk Factors
- Going concern risk: cash only sufficient into Q4 2026 without additional funding.
- No guarantee that licensing negotiations or potential investment will materialize.
- Zero revenue and continued operating losses; dependent entirely on external financing.
- Phase 2b study initiation and all future development contingent on securing funding/partnership.
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3339923 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 11w ago | Press Release | — | awaiting T+20 | — | — |
Jul 22, 2026 13w ago | Press Release | — | awaiting T+20 | — | — |
Jun 11, 2026 19w ago | Press Release | — | awaiting T+20 | — | — |
Jun 8, 2026 20w ago | Press Release | — | awaiting T+20 | — | — |
Apr 23, 2026 26w ago | Press Release | — | awaiting T+20 | — | — |
Apr 15, 2026 27w ago | Press Release | — | awaiting T+20 | — | — |
Apr 9, 2026 28w ago | Press Release | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers